Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6082164 | 0.85 | CCNT1 (0.36) | PTGS2PTGS1PDE4APDE4CPDE4D | |
| SCHEMBL6082905 | 0.81 | CYP19A1 (0.40) | — | |
| SCHEMBL6083735 | 0.81 | PIK3CA (0.38) | PTGS2PTGS1PDE4APDE4CPDE4D | |
| SCHEMBL6082538 | 0.80 | MEN1 (0.36) | PTGS2PDE4APDE4CPDE4D | |
| SCHEMBL6083004 | 0.79 | KDM4E (0.36) | PTGS2PTGS1PDE4APDE4CPDE4D | |
| SCHEMBL6084013 | 0.79 | SCN9A (0.41) | — | |
| SCHEMBL6081906 | 0.77 | CCNT1 (0.36) | PTGS2PTGS1PDE4APDE4CPDE4D | |
| SCHEMBL6084793 | 0.76 | CCNT1 (0.34) | PTGS2PDE4APDE4CPDE4D | |
| SCHEMBL6103842 | 0.76 | DAGLA (0.33) | PDE4APDE4CPDE4D | |
| SCHEMBL6082822 | 0.72 | KDM5A (0.38) | PDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067658-B2 | Pyridino and pyrimidino pyrazinones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-27 | — | — | US | disclosed |
| US-20040082784-A1 | Pyridino and pyrimidino pyrazinones | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-04-29 | — | — | US | disclosed |
| WO-2004031189-A1 | PYRIDINO AND PYRIMIDINO PYRAZINONES FOR TREATMENT OF ANXIETY AND DEPRESSION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082784-A1 | Pyridino and pyrimidino pyrazinones | CRHR1, CRHR2, CRH | PTGS2 1094/4885PTGS1 601/4885PDE4A 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.